 - Concomitant Medical Conditions: a Significant concomitant medical conditions defined as historical or current evidence of clinically significant uncontrolled disease of any body system. Significant is defined as any disease that, in the opinion of the investigator, would confound the interpretation of the study results if the diseasecondition exacerbated during the study: significant renal impairment, which based on the opinion of the investigator, would preclude the subjects participation in the study and current active liver or biliary disease with the exception of Gilberts syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment. NOTES: Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice, or cirrhosis and Chronic stable hepatitis B and C e.g., presence of hepatitis B surface antigen HBsAg or positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment are acceptable if subject otherwise meets entry criteria. b A severe physical obstruction of the nose e.g., deviated septum or nasal polyp or frequent bleeding of the nose that could affect the deposition of double blind intranasal study drug. c Current or history of a Candida infection of the nose or oropharynx, shingles, chickenpox, measles, ocular herpes simplex. d Known hypersensitivity to corticosteroids or any excipients in the product. e Recent nasal septal surgery or nasal septal perforation. f Subjects start, discontinue or change desensitization treatment within 30 days prior to Visit 1. g Bacterial or viral infection of the eyes or upper respiratory tract within two weeks of Visit 1 or during the screening period. h Asthma, with the exception of mild intermittent asthma. i Diagnosis of rhinitis medicamentosa, vasomotor AR or eosinophil rhinitis. 